3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
149
Lymphoma
60
Precursor Cell Lymphoblastic Leukemia-Lymphoma
47
Lymphoma, Large B-Cell, Diffuse
46
Leukemia
44
Lymphoma, Follicular
39
Lymphoma, Non-Hodgkin
35
Multiple Myeloma
33
Leukemia, Lymphocytic, Chronic, B-Cell
28
Leukemia, Myeloid, Acute
25
Burkitt Lymphoma
24
Neuroblastoma
21
Lymphoma, Large-Cell, Immunoblastic
16
Hodgkin Disease
16
Lymphoma, Mantle-Cell
14
Neoplasms
13
Triple Negative Breast Neoplasms
12
Lymphoma, B-Cell, Marginal Zone
11
Sarcoma
10
Inflammatory Breast Neoplasms
10
Rhabdomyosarcoma
8
Recurrence
8
Neoplasms, Plasma Cell
8
Myelodysplastic Syndromes
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Graft vs Host Disease
8
Lymphoma, T-Cell, Peripheral
7
Lymphoma, Large-Cell, Anaplastic
7
Leukemia, Biphenotypic, Acute
7
Lung Neoplasms
6
Interventions
Rituximab
2
Cytarabine
2
ponatinib
1
ibrutinib
1
ibritumomab tiuxetan
1
cirmtuzumab
1
amonafide
1
acalabrutinib
1
Vincristine
1
Prednisone
1
Melphalan
1
Imatinib Mesylate
1
Etoposide
1
Doxorubicin
1
Daunorubicin
1
Cyclophosphamide
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphatic Diseases
×
Cyclophosphamide
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled